Targeted Therapy (Investigational)
44 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (Investigational) (23)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Milciclib |
Gamma-Secretase / CDK Inhibitor | Solid Tumour (Sarcoma) | ||
|
Molecule
Milciclib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
||||
Napabucasin |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Napabucasin
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Navoximod |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Navoximod
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Nirogacestat |
Gamma-Secretase / CDK Inhibitor | Solid Tumour (Sarcoma) | ||
|
Molecule
Nirogacestat
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
||||
PRN1371 (Investigational FGFR) |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
PRN1371 (Investigational FGFR)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Seliciclib (CDK Inhibitor) |
Gamma-Secretase / CDK Inhibitor | Solid Tumour (Sarcoma) | ||
|
Molecule
Seliciclib (CDK Inhibitor)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
||||
Selumetinib Sulfate |
DNA Damage Response Inhibitor | Solid Tumour | ||
|
Molecule
Selumetinib Sulfate
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
||||
Simtuzumab |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Simtuzumab
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Telaglenastat |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Telaglenastat
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Tunlametinib |
DNA Damage Response Inhibitor | Solid Tumour | ||
|
Molecule
Tunlametinib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
||||
Zoldonrasib |
RAS(ON) G12D-Selective Tri-Complex Inhibitor | Solid Tumour | ||
|
Molecule
Zoldonrasib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
RAS(ON) G12D-Selective Tri-Complex Inhibitor |
||||
MilciclibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
|
NapabucasinTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
NavoximodTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
NirogacestatTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
|
PRN1371 (Investigational FGFR)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
Seliciclib (CDK Inhibitor)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
|
Selumetinib SulfateTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
|
SimtuzumabTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
TelaglenastatTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
TunlametinibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
|
ZoldonrasibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
RAS(ON) G12D-Selective Tri-Complex Inhibitor |
|